Rheumatology JC083: Multiple Joint Pain: Rheumatoid Arthritis, Osteoarthritis, The Concept Of Spondyloarthritis Flashcards

1
Q

Arthropathy classification

A

Inflammatory arthritis (persistent inflammation —> cause joint destruction):
1. RA
- Rheumatism
- Undifferentiated arthritis

  1. CT disease / SLE (minimal inflammation)
    - Jaccoud’s arthropathy
  2. Spondyloarthritis
    - AS
    - Psoriatic arthritis
    - IBD-related
    - Reactive arthritis
  3. Crystal arthritis
    - Gout
    - Pseudogout

Non-inflammatory arthritis:
1. OA
2. Fibromyalgia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Clinical features of different arthritis: History taking

A

RA:
- younger age
- **insidious onset
- **
polyarthritis
- **small hand joints (MCP, PIP) —> subluxation + ulnar deviation over MCP joint
- sparing DIP joints
- **
early morning stiffness >=30 mins

Spondyloarthritis:
- younger age
- **insidious onset
- mono / polyarthritis
- **
any joint can be involved
- **psoriasis (DIP joint with onycholysis), IBD, STD / dysentery, uveitis
- **
back pain
- family history

Osteoarthritis:
- **insidious onset
- **
weight bearing joints, DIP joints (nodal OA)
- older age

Gout:
- **acute onset
- 1st MTP joint involvement (any joint can be involved after MTP joint)
- usually **
self-limiting
- sometimes ***fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

P/E of arthritis

A
  1. Monoarthritis
    - Gout
    - OA
    - Spondyloarthritis
  2. ***Polyarthritis
    - RA (symmetrical small hand joints)
  3. Oligoarthritis (a few joints)
    - Spondyloarthritis (e.g. Psoriatic arthritis)
  4. ***Symmetrical
    - RA
  5. Asymmetrical
    - Spondyloarthritis (sometimes can mimic RA as symmetrical)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Osteoarthritis (OA)

A
  • Commonest non-inflammatory arthritis
  • Prevalence ↑ steeply with age (75% women >=65 yo)
  • Primary vs Secondary OA

***Primary (JC Surgery Upper limb painful conditions):
- Wear + Tear

***Secondary:
- Post-traumatic
- Post-inflammation (e.g. Post-RA, Post-Psoriatic arthritis)
- Post-infection

Sites:
- Weight bearing joints: Knee, Hips, Spine
- **CMC joint (wrist)
- **
DIP joint
- Trapeziometacarpal joints
—> >=3 joints involved —> ***Generalised OA

P/E:
- **Crepitus
- **
Minimal swelling

Imaging features:
- Loss of joint space (loss of cartilage)
- Osteophyte (marginal, abnormal bone proliferation)
- Subchondral cyst
- Subchondral sclerosis (sclerosed area: dead bone)
- **Preserved bone density (vs RA)
- **
Synovial hypertrophy
- Thickened capsule
- Joint deformity

(From JC Surgery Upper limb painful conditions:
Clinical features:
1. Pain on loading, relieved by rest
3. Stiffness, Swelling
4. Osteophytes —> Heberden’s nodes (DIP) + Bouchard’s nodes (PIP) —> may block movement / loss of ROM
5. Deformity / Instability of joint
6. Diminished grip + pinch strength —> unable to perform ADL

Radiological changes:
1. Loss of joint space (vs Widening of joint space in RA initially)
2. Osteophyte
3. Subchondral sclerosis
4. Subchondral cysts)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Rheumatoid arthritis (RA)

A
  • Commonest autoimmune inflammatory polyarthritis
  • found in all races

Epidemiology:
- 1-2% in Caucasians
- 0.3-0.4% in Chinese
- Rare in blacks
- Peak age of onset: **35-55 yo
- **
F:M = 3:1

Pathology:
- Synovial **proliferation (thickening) + **inflammation
- Insidious onset

Site (44 Joint count):
1. Appendicular
- ***hands / feet: MCP + PIP (earliest changes in 2nd + 3rd MCP + 3rd PIP) (DIP rare)
- wrists, elbows, knees, ankles, shoulders, hips

  1. Axial skeleton
    - apophyseal + atlantoaxial joints of ***cervical spine (esp. C1, C2 joints)

Features:
Disease activity:
1. Pain
2. **Swelling
3. **
Stiffness (morning)
4. Functional limitation

Investigations:
1. Clinical:
- **DAS (disease activity) score
—> Swollen joint count
—> Tender joint count
—> ESR / CRP
—> Global assessment of health
- Swollen joint count
- Duration of stiffness
2. **
CRP / ESR
3. USG
4. MRI
5. ***Extra-articular features (e.g. rheumatoid nodules, pulmonary fibrosis, amyloidosis, neuropathy)

Disease damage:
1. Pain
2. Less swelling
3. Deformity
- **Subluxation (partial dislocation) (C1, 2, MCP, ulnar deviation, carpal bone fusion) / **Dislocation
- **Tendon rupture
4. **
Secondary OA
5. Functional limitation
6. Post-inflammatory ***hyperpigmentation of joints

Investigations:
1. X-rays
2. CT (not useful to assess activity ∵ cannot see degree / amount of inflammation —> but can see bone destruction / deformity)
3. Extra-articular features (e.g. rheumatoid nodules, pulmonary fibrosis, amyloidosis, neuropathy)

Signs:
1. **Swan neck deformity (rupture of extensor tendon at DIP level —> unopposed flexion at DIP)
2. **
Boutonniere deformity (rupture of extensor tendon at PIP level —> unopposed flexion at PIP)
3. **Mallet finger
4. MCP ulnar deviation
5. Z-thumb (SpC Revision)
6. Extra-articular features
- **
Eyes: scleritis, keratoconjunctivitis
- Pleura: effusion
- **Lung: fibrosis, nodules
- LN: reactive lymphadenopathy
- **
Pericardium: effusion
- Spleen: splenomegaly (Felty syndrome (self notes))
- **Gut, Kidney: amyloidosis
- **
BM: anaemia of chronic disease, thrombocytosis (if severe inflammation)
- Muscle: wasting (common, ∵ disuse atrophy)
- Skin: thinning, ulceration (∵ vasculitis)
- ***Nervous system: peripheral neuropathy (∵ vasculitis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pathogenesis of RA (from MSS15)

A

Causes:
- Genetics

  • Environment (smoking, bacteria, dust / silica)
    —> trigger inflammation in mucosal sites e.g. gums, lungs, gut
  • Autoimmune
    1. Activation of immune system
    —> minor trauma **↑ expression of citrullinated proteins in normal healthy joints (joint: second hit)
    —> osteoclasts express enzyme that also **
    ↑ citrullination of collagen 2 in cartilage leading to attack by AutoAb
    —> ***APCs + dendritic cells presenting citrullinated proteins (post-translational modification of proteins) to immune system
  1. AutoAb formation (can be detected before disease onset)
  2. CD4 Th cells
    —> initiate response by reacting with an agent to produce cytokines
    —> stimulate ***macrophages (through IFNγ), Th17 (through IL17)
  3. Macrophage infiltration
    —> with release of TNFα + IL1 (intensity of infiltration correlates with disease activity and radiological progression)
    —> 1. stimulate synovial cells to produce **enzymes that destroy cartilage
    —> 2. +ve feedback between TNFα and factors by fibroblasts: chemotactic for **
    monocytes
    —> 3. AutoAb to citrullinated peptide (CCP)
  4. Rheumatoid factor
    —> serum IgM / IgA AutoAb that bind to Fc IgG (antibody against Fc portion of IgG)
    —> Immune complex formation

End result:
**Acute **destructive **inflammatory **synovitis
—> AutoAb against citrullinated vimentin (structural filament in fibroblasts): **cross reactive with other citrullinated antigen
—> lead to osteoclast-dependent **
bone destruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

***Diagnosis of RA (ACR-EULAR classification criteria)

A

Diagnosis: Clinical features

ACR-EULAR classification criteria (only ***helps to diagnose disease, NOT diagnostic)
Target population:
- >=1 joint with definite clinical synovitis (swelling)
- with synovitis not explained by another disease

***記: Joint involvement, Serology, Acute-phase reactant, Duration

Categories A-D (***>=6/10 needed for classification of patient as definite RA):
A. Joint involvement:
- 1 large joint
- 2-10 large joints
- 1-3 small joints (+/- large joints)
- 4-10 small joints (+/- large joints)
- >10 joints (>=1 small joints)

B. Serology (**RF, **ACPA: both specific for RA, RF can be elevated in chronic inflammation / infection, ACPA more specific)
- Negative RF + Negative ACPA
- Low-positive RF / Low-positive ACPA
- High-positive RF / High-positive ACPA

C. Acute-phase reactant
- Normal CRP + Normal ESR
- Abnormal CRP / Abnormal ESR

D. Duration of symptoms
- <6 weeks
- >=6 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Rheumatoid factor

A
  • AutoAb (IgM) against IgG
  • ***Not sensitive (many RA patients do not have RF, many false negative) —> Rmb: Clinical features more important than markers!!!
  • ***Specific but less than Anti-CCP (SpC Revision)
  • ***Not correlate with disease activity
  • High levels in RA —> ***Poor prognosis (∵ more joint damage in shorter time)

Causes:
1. RA
2. **Sjögren’s syndrome
3. **
Chronic infection / Lymphoma
4. Elderly, ***Healthy individuals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ACPA / Anti-CCP

A
  • Anti-cyclic citrullinated peptide Ab
  • **Low sensitivity, **High specificity (>90% with positive clinical features)
  • ***Not correlate with disease activity
  • Predict **progressive + **erosive disease —> need to treat aggressively
  • Specificity further improves when screened together with RF (if both positive —> high chance of RA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

***Radiological features of RA

A
  1. **Soft tissue swelling + **Widened joint space (Initial stage)
    - synovial inflammation + effusion
  2. ***Juxta-articular osteoporosis (osteopenia next to affected joint)
    - hyperaemia + disuse
  3. **Joint space narrowing
    - destruction of **
    cartilage by ***Pannus (aggressive macrophage- and fibroblast-like mesenchymal cells, macrophage-like cells and other inflammatory cells that release collagenolytic enzymes)
  4. **Peri-articular erosions
    - Pannus destruction of unprotected **
    bone at insertion of joint capsule
    (- vs Juxta-articular erosions: Gout)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Spondyloarthritis (SpA)

A

Umbrella term: spectrum of disease

Axial SpA:
- AS (Prototype, with radiological sacroilitis)
- Psoriatic arthritis
- IBD-related SpA
- Reactive arthritis
- Undifferentiated SpA

Peripheral SpA:
- No spine / axial joints involved

Clinical features:
- **Spondylitis (inflammation of spine)
- **
Peripheral arthritis (inflammation of peripheral joints)
- **Enthesitis (Archilles tendinitis, plantar fasciitis, chest wall tendons)
- **
Anterior uveitis
- ***Aortitis
- Associated with HLA-B27
- Other associated features: Psoriasis (scaly plaques, onycholysis, dactylitis (sausage finger), IBD, Dysentery, STD

Pathognomonic findings of Axial SpA:
- **Inflammation + **Osteodestruction + ***Osteoproliferation
—> Final stage of AS: severe kyphosis of thoracic + cervical spine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

P/E of Spondyloarthritis

A
  1. ***Modified Schober (spinal mobility)
    - 5cm below imaginary line between PSIS + 10 cm above (i.e. 15cm apart)
    - bend forward
    - ↑ >=5 cm: normal
  2. Lateral spinal flexion
    - standing distance between finger and floor —> bend sidewards —> mark new distance
    - no reference values
  3. Occiput to Wall / Tragus to Wall
    - max effort to move head against wall —> measure distance
  4. Cervical rotation
    - rotate neck maximally to side —> goniometer to measure angle
  5. Intermalleolar distance
    - separate legs as far as possible —> measure distance between 2 medial malleoli

(6. Chest expansion
- normal chest expansion >=5cm (CL Lai))

(7. **Question mark deformity (ascending fusion from SI joint from caudal to cranial) —> compensate by **knee flexion + ***hip extension to look up —> treatment: osteotomy to break bones up and bring spine up straight) (From SC044)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

***HLA-B27

A
  • a Gene
  • 8-9% Caucasian carrying HLA-B27 gene (***lower in Asians)
  • Positive in ***90-95% AS patients
  • Positive in 46-75% Axial SpA patients
  • ***Not sensitive / specific in SpA diagnosis
  • Have prognostic value —> **Only those with HLA-B27 will have higher chance to progress to AS (*spinal fusion + new bone formation)

3 theories:
1. Peptide presentation: B27 presenting an “arthritogenic” / “enthesitogenic” peptide to CD8+ T cells (i.e. direct T cell attack cells presenting B27 gene)
2. Misfolding: B27 heavy chain tends to misfold during synthesis in the ER —> provoke ER stress response —> cytokine secretion (e.g. IL23) —> joint inflammation
3. Cell surface markers: B27 expressed on cell surface as dimers / multimers —> engage receptors on T cells, NK cells, APCs —> affect their functioning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

***AS: Modified New York classification criteria

A

MUST have AS radiological criteria + 1 clinical criteria

  1. Clinical criteria
    - low back pain + stiffness **>=3 months (improve with exercise, not relieved by rest)
    - limitation of motion of **
    lumbar spine in both sagittal + frontal planes
    - limitation of ***chest expansion relative to normal values corrected for age / sex
  2. **Radiological criteria (MUST)
    - **
    Sacroiliitis: grade >2 bilaterally / grade 3-4 unilaterally
    - erosion / fusion of SI joint
    - grade 2: normal joint space
    - grade 3: **narrowed / **widened joint space
    - grade 4: ***fused completely
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

***Disease diagnosis of SpA

A
  • ***MNY criteria
    OR
  • ***ASAS classification criteria for axSpA (incorporate MRI: detect inflammation before joint damage)
  1. ***Axial criteria:
    - Sacroiliitis on imaging + >=1 SpA feature
    or
    - HLA-B27 + >=2 SpA features
  2. ***Peripheral criteria:
    - Arthritis / Enthesitis / Dactylitis + other SpA feature

X-ray sacroiliitis:
- takes years for X-ray changes
- delay in diagnosis: up to 6-11 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Disease activity assessment

A

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

17
Q

Using spine MRI to diagnose SpA

A

Inflammatory markers correlated poorly with disease activity (***unlike RA)

Inflammation (hyperintense signals affecting spine / SI joint):
- Anterior / Posterior spondylitis (*corner inflammatory lesions (CIL))
- Spondylodiscitis
- Arthritis of costovertebral joints
- Arthritis of zygoapophyseal joints
- Enthesitis of spinal ligaments

Structural changes:
- Fatty deposition (fatty corner lesions (FCL))
- **Erosions
- **
Syndesmophytes (calcifications / heterotopic ossifications inside spinal ligament / of annulus fibrosus (web))
- ***Ankylosis

18
Q

Treatment of Inflammatory arthritis

A

Goal:
1. Suppress disease activity
2. Prevent joint damage
3. Preserve normal function
4. Pain relief

Treatment:
1. Education
2. Physical therapy (physio/occupational therapy)
3. Medical therapy
4. Surgery (correct deformity)

Medications:
***Symptom-modifying anti-rheumatic drug (cannot modify disease course / prevent joint damage)
1. NSAID (e.g. diclofenac)

***Disease-modifying anti-rheumatic drug (DMARDs) (long onset of action: several months)
1. Conventional synthetic DMARD (csDMARD) (e.g. methotrexate, sulfasalazine, leflunomide, HCQ)
2. Biological DMARD (bDMARD) (e.g. anti-TNF, anti-IL6, anti-IL17, anti-CD20)
3. Targeted synthetic DMARD (tsDMARD) (e.g. Janus kinase inhibitor: Tofacitinib)

***Steroid
- high dose: DMARD
- low dose: SMARD

OT surgeries
1. Patient factors
- location of damaged joint
- expectation of patient
- age

  1. Surgeon factors
    - availability of expertise
    - experience of surgeon
19
Q

Conventional Synthetic DMARDs (csDMARDs) (From MSS08)

A
  1. Cytotoxic agents
    - Methotrexate —> Antimetabolite
    - Azathioprine / 6-MP —> Antimetabolite
    - Leflunomide
    - Cyclophosphamide —> Alkylating agent
  2. Sulfasalazine
  3. Antimalarial drugs
    - Chloroquine
    - Hydroxychloroquine
  4. Immunosuppressants
    - Cyclosporine —> Calcineurin inhibitor
    - Mycophenolate mofetil —> inhibit IMP dehydrogenase
  5. Gold (no longer recommended: toxicities vs efficacy)
    - Aurothiomalate
    - Auranofin
20
Q

Biological DMARDs (bDMARDs) (From MSS08)

A
  1. TNF-α blocking agents
    - **Etanercept, **Infliximab, ***Adalimumab, golimumab, certolizumab
  2. IL-1 receptor antagonist
    - Anakinra
  3. IL-6 receptor antagonist
    - ***Tocilizumab
    - Sarilumab
  4. T-cell co-stimulation modulator
    - ***Abatacept (contain CTLA-4)
  5. B-cell cytotoxic agent
    - ***Rituximab (Anti-CD20) —> Complement activation (MAC) + ADCC

Indication:
- moderate to severe RA not responded adequately to >=1 traditional DMARDs

Precaution:
1. T-cell co-stimulation modulator / B-cell cytotoxic agent / IL-1 receptor antagonists
—> NOT recommended to use in combination with TNF inhibitors
—> ↑ risk of infection
2. Increase risk of ***TB infection

21
Q

Targeted Synthetic DMARDs (tsDMARDs) (From MSS08)

A

Janus-activated Kinase / JAK Inhibitors (***Tofacitinib, Baricitinib)

Mechanism:
Binds to ATP binding site of catalytic domain of JAK
—> inhibit Janus-activated kinase (JAK)
—> ↓ signaling by **IFN and **IL-6

Characteristics:
- Orally bioavailable
- Indicated for patients with inadequate responses to 1 or more DMARDs

Precaution:
- Drug interactions
—> Tofacitinib: metabolised by CYP3A4
—> Baricitinib: metabolised by organic anion transporter 3

Adverse effects:
1. ↑ risk of **infection (esp. Herpes virus due to inhibition of Type 1 interferons —> consider zoster vaccination prior to treatment)
2. ↑ risk of **
non-melanoma skin cancer
3. ↑ plasma level of **liver enzymes (liver function monitoring)
4. ↑ plasma level of **
lipoprotein (LDL and HDL)
5. GI perforation
6. Potential risk of ***anaemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia (due to many haematopoietic growth factors including erythropoietin and granulocyte macrophage-colony stimulating factor signaling through JAK phosphorylation)

22
Q

Psoriatic arthritis (SpC Med PP)

A

Types:
1. Asymmetrical inflammatory oligoarthritis
2. Symmetrical polyarthritis
3. Distal IPJ arthritis
4. Psoriatic spondylitis
5. Arthritis mutilans